Bio-Rad (BIO) Q4 2025 earnings review
Clinical Diagnostics Rescues the Quarter, But 2026 Outlook is Tepid
Bio-Rad delivered a mixed Q4 to close a volatile 2025. While reported revenue grew 3.9% driven by a sharp rebound in Clinical Diagnostics (+5.6% currency-neutral), the Life Science segment remains in contraction (-4.0% CN) due to constrained academic and biotech funding. Profitability underwhelmed: Non-GAAP Operating Margin compressed 180 bps YoY to 12.0%, and Non-GAAP EPS of $2.51 missed the prior year's $2.90. A massive $173M impairment charge for R&D discontinuation signals a portfolio cleanup. Guidance for 2026 implies barely-there growth (0.5-1.5%) and flat margins, suggesting the 'transition' period is far from over.
🐂 Bull Case
Clinical Diagnostics finally broke its stagnation with 5.6% currency-neutral growth in Q4, driven by quality controls and blood typing. This segment accounts for ~60% of revenue, providing a stable floor even as Life Science struggles.
Despite earnings volatility, Bio-Rad generated $532M in operating cash flow and $375M in free cash flow for FY25. The company ended the year with $530M in cash and short-term investments of $1.0B, providing ample capital allocation optionality.
🐻 Bear Case
Life Science revenue fell 4.0% (CN) in Q4, deteriorating from Q3 levels. The 'constrained academic research and biotech funding' narrative has not improved, and 2026 guidance (0-1% growth for Life Science) suggests no V-shaped recovery is imminent.
Non-GAAP Gross Margin fell 140 basis points YoY to 52.5% in Q4. Management flagged 'shifts in geographical mix' and new tax legislation impacts. With 2026 operating margin guided flat (12.0-12.5%), efficiency gains remain elusive.
⚖️ Verdict: 🔴
Bearish. The recovery in Clinical Diagnostics is the only green shoot in a tough report. Shrinking Life Science revenue, contracting margins, and a large impairment charge cloud the picture. The 2026 outlook for ~1% growth and flat margins offers little reason for immediate optimism.
Key Themes
Significant R&D Impairment Charge
Bio-Rad recorded a $172.8 million impairment charge in Q4 related to purchased intangibles and the discontinuation/reprioritization of certain R&D programs. This substantial write-down drove a GAAP operating loss of $118.9 million for the quarter and raises questions about capital allocation efficiency in previous years.
Clinical Diagnostics Accelerates
After three quarters of flat-to-negative performance, Clinical Diagnostics surged 5.6% (CN) in Q4. Growth was broad-based across quality controls, blood typing, and diabetes products, with sales increasing in all regions. This marks a significant turnaround from the China reimbursement headwinds that plagued earlier quarters.
Life Science Funding Drought
The Life Science segment contracted 4.0% (CN) in Q4, worsening from Q3's 1.5% decline. The company explicitly blamed 'constrained academic research and biotech funding.' Unlike the Diagnostics rebound, Life Science shows no sign of stabilizing, with FY26 guidance calling for meager 0.0% to 1.0% growth.
Sartorius Investment Volatility
Bio-Rad's ownership in Sartorius AG continues to distort GAAP results. In Q4, a fair market value gain contributed to $720M in GAAP Net Income, despite an operating loss. In FY24, this line item caused a $1.8B loss. Investors must strictly look at Non-GAAP figures to understand operational health.
Digital PCR Portfolio Expansion
The integration of Stilla Technologies (acquired mid-2025) and the expanded ddPCR product portfolio are showing 'initial market adoption.' While not yet enough to offset broader Life Science weakness, this remains the company's primary technology growth engine.
Other KPIs
Decelerating. Down 140 basis points from 53.9% in 24Q4. The full-year margin of 53.3% also trailed the prior year's 55.0%, reflecting persistent pressure from product mix and lower absorption.
Improving. Up nearly 30% from $289.6M in FY24. Operating cash flow grew to $532M, demonstrating effective working capital management despite the earnings headwinds.
Miss. Down 13% YoY from $2.90 in 24Q4. The decline was driven by lower gross margins and a higher effective tax rate (25.3% vs 20.9%).
Guidance
Stable/Slight Acceleration. Compares to -0.1% CN growth in FY25. Essentially implies another year of stagnation, with the mid-point (1.0%) suggesting no return to robust growth.
Stable. The range brackets the FY25 result of 12.1%. Management is not forecasting any meaningful margin expansion despite cost controls and restructuring efforts.
Stabilizing. Improves slightly from -1.3% in FY25, but indicates continued lack of momentum in the core research market.
Key Questions
Impairment Details
What specific R&D programs were discontinued to trigger the $172.8M impairment charge, and does this signal a strategic exit from certain Life Science categories?
Margin Stagnation
With a flat operating margin guide for FY26 (12.0-12.5%), when can investors expect the benefits of recent restructuring and the Stilla integration to drive leverage?
China Diagnostics Rebound
Q4 Diagnostics strength was notable. How much of this +5.6% growth was driven by China recovering versus strength in other regions, and is the diabetes reimbursement headwind fully annualized?